Fast Market Research announces the availability of the new Global Markets Direct report, "Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H1 2017", on their comprehensive research portal

Boston, MA -- (SBWire) -- 04/06/2017 --Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H1 2017, provides an overview of the Venous Leg Ulcers (Crural ulcer) (Dermatology) pipeline landscape.

Venous leg ulcers develop when persistently high blood pressure in the veins of the legs (venous hypertension) causes damage to the skin, which eventually breaks down and forms an ulcer. Symptoms include swollen ankles filled with fluid that temporarily hold the imprint of finger when pressed (known as pitting edema), discoloration and darkening of skin around the ulcer (known as hemosiderosis), hardened skin around the ulcer, which may make leg feel hard and resemble the shape of an upside-down champagne bottle (known as lipodermatosclerosis), small, smooth areas of white skin, which may have tiny red spots (known as atrophie blanche).

Get More Details on this Report and a Full Table of Contents at Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H1 2017

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Venous Leg Ulcers (Crural ulcer) (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Venous Leg Ulcers (Crural ulcer) (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Venous Leg Ulcers (Crural ulcer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Unknown stages are 3, 7, 1, 5 and 1 respectively.

Venous Leg Ulcers (Crural ulcer) (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Report Scope

-The pipeline guide provides a snapshot of the global therapeutic landscape of Venous Leg Ulcers (Crural ulcer) (Dermatology).

-The pipeline guide reviews pipeline therapeutics for Venous Leg Ulcers (Crural ulcer) (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

-The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

-The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

-The pipeline guide reviews key companies involved in Venous Leg Ulcers (Crural ulcer) (Dermatology) therapeutics and enlists all their major and minor projects.

-The pipeline guide evaluates Venous Leg Ulcers (Crural ulcer) (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

-The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

-The pipeline guide reviews latest news related to pipeline therapeutics for Venous Leg Ulcers (Crural ulcer) (Dermatology)

Reasons to Get this Report

-Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

-Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

-Find and recognize significant and varied types of therapeutics under development for Venous Leg Ulcers (Crural ulcer) (Dermatology).

-Classify potential new clients or partners in the target demographic.

-Develop tactical initiatives by understanding the focus areas of leading companies.

-Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Companies Mentioned in this Report: Adocia, CardioVascular BioTherapeutics Inc, CytoTools AG, Factor Therapeutics Ltd, FirstString Research Inc, Mallinckrodt Plc, MediWound Ltd, NovaLead Pharma Pvt Ltd, Promore Pharma, RegeneRx Biopharmaceuticals Inc, RMB-Research GmbH

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Drug Pipeline research reports at Fast Market Research

You may also be interested in these related reports:

-Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H2 2016
-Pressure Ulcers - Pipeline Review, H1 2017
-Functional (Non Ulcer) Dyspepsia - Pipeline Review, H1 2017
-Hemophilia A - Pipeline Review, H1 2016
-Systemic Sclerosis (Scleroderma) - Pipeline Review, H1 2017